Sugi Predict

Sugi Predict / Targets / DDIT3

DDIT3

DNA damage-inducible transcript 3 protein · P35638 · DDIT3 on Sugi Atlas →

552 patent compounds predicted against DDIT3, 413 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL16912990 SCHEMBL16912990 1.00 15/20
SCHEMBL16912991 SCHEMBL16912991 1.00 15/20
SCHEMBL16912994 SCHEMBL16912994 1.00 15/20
SCHEMBL16919785 SCHEMBL16919785 1.00 15/20
SCHEMBL16919791 SCHEMBL16919791 1.00 15/20
SCHEMBL16913004 SCHEMBL16913004 1.00 14/20
SCHEMBL16913006 SCHEMBL16913006 1.00 14/20
SCHEMBL16919786 SCHEMBL16919786 1.00 14/20
SCHEMBL16919789 SCHEMBL16919789 1.00 14/20
SCHEMBL16919790 SCHEMBL16919790 1.00 14/20
SCHEMBL16919794 SCHEMBL16919794 1.00 14/20
SCHEMBL16913001 SCHEMBL16913001 1.00 13/20
SCHEMBL16919773 SCHEMBL16919773 1.00 13/20
SCHEMBL16919787 SCHEMBL16919787 1.00 13/20
SCHEMBL19250650 SCHEMBL19250650 0.87 13/20
SCHEMBL18709397 SCHEMBL18709397 0.61 13/20
SCHEMBL20296955 SCHEMBL20296955 0.61 13/20
SCHEMBL16921345 SCHEMBL16921345 0.74 11/20
SCHEMBL16919793 SCHEMBL16919793 0.68 11/20
SCHEMBL16921370 SCHEMBL16921370 0.76 10/20

Clinical trials — most relevant to DDIT3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Tumor Gene Expression in Women With Ovarian Cancer PHASE4COMPLETED
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity PHASE2RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer. PHASE2COMPLETED
Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) PHASE1/PHASE2UNKNOWN
Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer PHASE2UNKNOWN
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma PHASE2COMPLETED
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 PHASE1/PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Autophagy Bladder Cancer nanUNKNOWN
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients nanACTIVE_NOT_RECRUITING
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction nanCOMPLETED
Perfusion-Induced Hyperthermia for Metastatic Carcinoma nanCOMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility nanRECRUITING
Genetic Study of Age-Related Macular Degeneration nanCOMPLETED
2-A-Day Study: Twice a Day Meals Study. nanCOMPLETED
Unusual Infiltrative Patterns of Malignant Cells in Endometrial Carcinoma and Immunohistochemical Expression of P53 nanUNKNOWN
ADAR1 Expression Level in Rectal Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a DDIT3 binder may also engage these)

ProteinNameSimilarity
Q62857 — 1.000 Q62857 →
Q0IIB6 — 0.998 Q0IIB6 →
P35639 — 0.997 P35639 →
P14607 — 0.995 P14607 →
Q92172 — 0.994 Q92172 →
P41224 — 0.992 P41224 →
O54968 — 0.991 O54968 →
Q60795 — 0.991 Q60795 →
Q6PZD9 — 0.989 Q6PZD9 →
Q9ES19 — 0.989 Q9ES19 →
Q3ZCH6 — 0.989 Q3ZCH6 →
Q61501 — 0.988 Q61501 →
P56931 — 0.988 P56931 →
Q5NUA6 — 0.988 Q5NUA6 →
Q9Y6A5 — 0.988 Q9Y6A5 →
Q06507 — 0.988 Q06507 →
Q9DB00 — 0.988 Q9DB00 →
P17667 — 0.987 P17667 →
Q949U2 — 0.987 Q949U2 →
Q8WMS3 — 0.987 Q8WMS3 →
Q9JLC6 — 0.987 Q9JLC6 →
Q80Y56 — 0.987 Q80Y56 →
Q28F43 — 0.987 Q28F43 →
Q9FY74 — 0.987 Q9FY74 →
P13349 — 0.987 P13349 →
Q7TN02 — 0.987 Q7TN02 →
Q8BG95 — 0.987 Q8BG95 →
P52730 — 0.987 P52730 →
Q9R0A0 — 0.987 Q9R0A0 →
Q9DA69 — 0.987 Q9DA69 →